Adaptimmune Therapeutics plc (ADAP) |
|
2.06 0.04 (1.98%)
|
12-02 16:00 |
|
Open: |
2 |
Pre. Close: |
2.02 |
|
High:
|
2.13 |
Low:
|
1.955 |
|
Volume:
|
596,886 |
Market Cap:
|
337(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:20:40 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.09 One year: 3.61 |
| Support: |
Support1: 1.83  Support2: 1.33 |
| Resistance: |
Resistance1: 2.65 Resistance2: 3.09 |
| Pivot: |
2.29  |
| Moving Average: |
MA(5): 2.1 MA(20): 2.2
MA(100): 1.77 MA(250): 2.11 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 13 %D(3): 26.5 |
| RSI: |
RSI(14): 52 |
| 52-week: |
High: 4.16 Low: 1 |
| Average Vol(K): |
3-Month: 537 (K) 10-Days: 388 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADAP ] has closed above bottom band by 13.9%. Bollinger Bands are 1.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.13 - 2.14 |
2.14 - 2.16 |
|
Low:
|
1.93 - 1.94 |
1.94 - 1.95 |
|
Close:
|
2.04 - 2.06 |
2.06 - 2.08 |
|
Company Description |
|
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. |
Headline News |
Fri, 02 Dec 2022
Pritzker Administration Announces Highly Effective, New HIV Treatment to be Available in Illinois - RiverBender.com
Thu, 01 Dec 2022
World AIDS Day: AIDS resources that are available in Fresno County - YourCentralValley.com
Fri, 18 Nov 2022
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent - Yahoo Finance
Wed, 16 Nov 2022
ADAP Advocacy Association Launches Ryan White Grantee 340B Project - Digital Journal
Mon, 14 Nov 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Raised to $3.00 - MarketBeat
Fri, 11 Nov 2022
Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing - The Business Journals
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
164 (M) |
|
% Held by Insiders
|
8.655e+007 (%) |
|
% Held by Institutions
|
0.1 (%) |
|
Shares Short
|
3,970 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.7272e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
24 |
|
Return on Equity (ttm)
|
-32.8 |
|
Qtrly Rev. Growth
|
1.754e+007 |
|
Gross Profit (p.s.)
|
238.86 |
|
Sales Per Share
|
-48.93 |
|
EBITDA (p.s.)
|
-5.19505e+007 |
|
Qtrly Earnings Growth
|
-1.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-2.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.05 |
|
Price to Cash Flow
|
6.03 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.34e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-03-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
